A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Publication Type:

Journal Article

Source:

European journal of cancer (Oxford, England : 1990) (2014)

Keywords:

2014, Clinical Research Division, July 2014

Abstract:

To evaluate the efficacy and safety of ramucirumab (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with dacarbazine in chemotherapy-naïve patients with metastatic melanoma (MM).